Single-cell transcriptomics of intraocular infiltrate in human HLA-B27-associated active anterior uveitis shows a unique composition and phenotype of leukocytes preferentially affecting dendritic cells.

A CRISPR-based method enables targeted knockouts and genetic screens in human dendritic cells.

CX3CR1-positive dendritic cells are altered in patients with non-infectious uveitis.

Dendritic cell recognition and processing of antigens from dead cells, utilising the Clec9A-damage recognition receptor, is controlled by a novel RNF41-ubiquitin-mediated regulatory pathway.

Probing of various culture conditions leads to fundamental advances in ex vivo production of plasmacytoid dendritic cells for use in immunotherapy.

A novel lncRNA marks the Irf8 downstream enhancer that is crucial for differentiation of plasmacytoid dendritic cells (pDC) and classical dendritic cells type 1 (cDC1) and confers feedback inhibition of Irf8 transcription.

A novel microscopy-based assay shows that dendritic cells encountering pathogenic stimuli form increased complexes of specific SNARE proteins, driving release of large amounts of inflammatory cytokines.

By using immune cells called dendritic cells to deliver drugs, it is possible to target and kill specific members of another class of immune cell, known as T cells, and to prevent these cells from attacking the body's own tissues in cases of autoimmune disease.

CD301b dendritic cells potently suppress antibody responses by limiting the activity of follicular helper T cells and germinal center B cells.

The receptor EBI2 is essential for correctly positioning CD4+ dendritic cells in the spleen so that they can present blood-borne antigens to T cells and thereby provoke an antibody response.